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ABSTRACT
Human blood dendritic cells (DCs) hold great potential for use in anticancer immunotherapies. CD1cC myeloid
DCs and plasmacytoid DCs (pDCs) have been successfully utilized in clinical vaccination trials against melanoma.
We hypothesize that combining both DC subsets in a single vaccine can further improve vaccine efficacy. Here,
we have determined the potential synergy between the two subsets in vitro on the level of maturation, cytokine
expression, and effector cell induction. Toll-like receptor (TLR) stimulation of CD1cC DCs induced cross-activation
of immature pDCs and vice versa. When both subsets were stimulated together using TLR agonists, CD86
expression on pDCs was increased and higher levels of interferon (IFN)-a were produced by DC co-cultures.
Although the two subsets did not display any synergistic effect on naive CD4C and CD8C T cell polarization,
CD1cC DCs and pDCs were able to complement each other’s induction of other immune effector cells. Themere
presence of pDCs in DC co-cultures promoted plasma cell differentiation from activated autologous B cells.
Similarly, CD1cC DCs, alone or in co-cultures, induced high levels of IFN-g from allogeneic peripheral blood
lymphocytes or activated autologous natural killer (NK) cells. Both CD1cC DCs and pDCs could enhance NK cell
cytotoxicity, and interestingly DC co-cultures further enhanced NK cell-mediated killing of an NK-resistant tumor
cell line. These results indicate that co-application of human blood DC subsets could render DC-based anticancer
vaccinesmore efficacious.
Abbreviations: CCR7, C-C chemokine receptor type 7; CTL, cytotoxic T lymphocyte; DC, dendritic cell; GM-CSF,
granulocyte-macrophage colony-stimulating factor; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin;
LPS, lipopolysaccharide; MFI, mean fluorescence intensity; MHC, major histocompatibility complex; MLR, mixed
lymphocyte reaction; mDC, myeloid DC; NK, natural killer; ODN, oligodeoxynucleotide; PBL, peripheral blood
lymphocyte; PBMC, peripheral blood mononuclear cell; pDC, plasmacytoid DC; PD-L1, programmed death-ligand 1;
PMA, phorbol 12-myristate 13-acetate; poly(I:C), polyinosinic-polycytidylic acid; PI, propidium iodide; SEB, Staphylo-
coccal enterotoxin B; TAA, tumor-associated antigen; Th, T helper; TLR, toll-like receptor; TNF, tumor necrosis factor
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Introduction
Dendritic cells (DCs) possess the ability to drive both adaptive and
innate immune responses and therefore play a central role in anti-
tumor immunity. Hence, they can be exploited for the treatment of
immunogenic cancers, such as melanoma.1,2 DC-based vaccines
consist of patient-derived DCs, which are stimulated and loaded
with tumor-associated antigens (TAAs) ex vivo, before being re-
infused into the patient. This form of immunotherapy aims at acti-
vating the patient’s own immune system to recognize and eradicate
tumor cells. DCs derived from monocytes or CD34C progenitor
cells are usually the main source of DCs used for vaccines.
Nevertheless, the use of naturally occurring DCs isolated from
blood has been recently hypothesized to improve therapeutic
responses, due to less extensive ex vivo culture periods.3
Several DC subsets can be identified in human peripheral
blood.4 They are divided into plasmacytoid DCs (pDCs) and
myeloid DCs (mDCs), with the latter being subdivided into
CD1cC (or BDCA1C) DCs and the rare CD141C (or BDCA3C)
DCs. mDCs and pDCs are functionally distinct, which is
reflected by their non-overlapping repertoire of expressed toll-
like receptors (TLRs).5-7 Cytokine secretion following stimula-
tion also differs between DC subsets. CD1cC DCs can secrete
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high levels of bioactive interleukin (IL)-12,8 an important cyto-
kine for the induction of T helper 1 (Th1) and cytotoxic T lym-
phocyte (CTL) responses.9,10 In contrast, pDCs can produce
massive amounts of type I interferons (IFNs) upon stimula-
tion.11 IFN-a can also take part in the skewing of Th1
responses,12 in addition to increasing the cytotoxic activity of
natural killer (NK) cells.13 These characteristics make both DC
subsets suitable for use in cancer immunotherapy. Indeed, vac-
cination with CD1cC DCs for prostate cancer was shown to be
safe and feasible.14 Our group has previously conducted phase I
clinical trials exploiting either pDCs or CD1cC DCs for vacci-
nation of melanoma patients, demonstrating the safety and effi-
cacy of this approach.15,16 These promising results raise the
question whether combining both DC subsets can further
improve immunological responses and clinical outcome.
In the current study, we have characterized the crosstalk
between human blood CD1cC DCs and pDCs by analyzing
maturation status and cytokine production after co-culture of
both subsets in the presence or absence of TLR stimulation. In
addition, functional implications of crosstalk-mediated effects
on other adaptive and innate immune cells, namely naive
CD4C and CD8C T cells, B cells and NK cells, were addressed.
We have shown that CD1cC DCs and pDCs are able to cross
activate each other. Although co-application of DC subsets did
not augment T cell polarization, it did allow for complementa-
tion of subset-specific effector functions, including induction of
plasma cell differentiation from B cells and secretion of high
levels of IFN-g by peripheral blood lymphocytes (PBLs) and
NK cells. Furthermore, DC co-cultures could synergistically
enhance NK cell-mediated killing of an NK-resistant tumor cell
line. These results indicate that combining the distinct qualities
of different human blood DC subsets may potentiate current
DC-based anticancer vaccines for optimal therapeutic outcome.
Results
TLR triggering of human CD1cC DCs or pDCs cross
activates bystander DCs
We first investigated whether human DC subsets can directly alter
each other’s activation status. Autologous human CD1cC DCs and
pDCs were isolated from peripheral blood and stimulated over-
night, either separately (single cultures) or together (co-cultures) at
a 1:1 ratio. The total number of DCs was kept constant between the
cultures. DCs were stimulated with a specific TLR ligand: CpG oli-
godeoxynucleotide (ODN) class C (CpG-C) for pDCs, polyino-
sinic-polycytidylic acid (poly(I:C)) for CD1cC DCs. In the absence
of TLR agonists, IL-3 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) were added to maintain the survival
of pDCs and CD1cC DCs, respectively. Subset-specific maturation
status was determined by flow cytometry analysis of the
co-stimulatory molecules CD86, CD80, and CD40, the maturation
marker CD83, the co-inhibitory molecule programmed death-
ligand 1 (PD-L1), C-C chemokine receptor type 7 (CCR7), and
major histocompatibility complex (MHC) class I and II molecules.
The presence of poly(I:C)-activated CD1cCDCs led to significantly
enhanced expression levels of CD86 (p D 0.0243), PD-L1
(pD 0.0002) andMHC class I (p< 0.0001) on unstimulated pDCs
(Fig. 1A). Conversely, immature CD1cC DCs significantly
upregulated CD86 (p D 0.0445), CD80 (p < 0.0001), PD-L1
(p< 0.0001), andMHC class I (pD 0.0014) and slightly downregu-
lated MHC class II (p D 0.0414), when co-cultured with CpG-C-
activated pDCs (Fig. 1B). When both subsets were stimulated
together, using their respective TLR agonists, pDCs showed
increased CD86 expression compared to CpG-C-stimulated pDCs
cultured separately (p D 0.0464), whereas CD1cC DCs showed a
trend toward increased PD-L1 expression (pD 0.0741). To exclude
the possibility that changes in DCmaturation status were the result
of a combination of stimuli, rather than crosstalk between DC sub-
sets, combinations of stimuli that were used for DC co-cultures
were also tested on DC single cultures. Incorporation of these extra
control groups did not change the abovementioned results qualita-
tively (Fig. S1 A and B). Of note, the combination of CpG-C and
poly(I:C) did not fully mature CD1cC DCs in both DC single cul-
tures and co-cultures, as co-stimulatory molecules were upregu-
lated less when poly(I:C) was used as the sole stimulus.
Next, cytokine secretion by human blood DCs was exam-
ined. Poly(I:C)-stimulated CD1cC DCs secreted IL-12p70, the
bioactive form of IL-12, although no detectable levels were
reached when a combination of poly(I:C) and CpG-C was used
(Fig. 1C, first panel and Fig. S1C). In contrast, CpG-C-stimu-
lated pDCs produced high levels of IFN-a. Interestingly, IFN-a
secretion was significantly augmented in DC co-cultures where
CpG-C and poly(I:C) were used, compared to CpG-C-
stimulated pDCs alone (p D 0.0255; Fig. 1C, second panel). Fur-
thermore, both subsets produced tumor necrosis factor (TNF)-a
upon TLR ligation. When poly(I:C)-stimulated CD1cC DCs
were co-cultured with immature pDCs, there was a trend
toward more TNF-a secretion compared to the corresponding
DC single cultures (p D 0.1537 when compared to poly(I:C)-
treated CD1cC DCs alone; Fig. 1C, third panel). These results
indicate that TLR triggering of one DC subset induces cross
activation of the other subset in culture. In addition, TLR
triggering of both DC subsets may induce further changes to
their phenotype and functionality, such as increased expression
of co-stimulatory molecules and secretion of cytokines.
To assess whether paracrine cytokine stimulation is the main
mechanism behind the upregulation of maturation markers
observed in the DC co-cultures, immature CD1cC DCs were cul-
tured with different concentrations of recombinant IFN-a or
TNF-a, whereas immature pDCs were cultured with different
combinations of recombinant TNF-a. IFN-a by itself induced
strong upregulation of CD86, CD80, PD-L1, and MHC class I on
CD1cC DCs (Fig. S2A), all to a similar extent as can be seen in the
DC co-cultures (Fig. 1). Incubation with TNF-a alone induced
upregulation of PD-L1 and MHC class I and a slight decrease of
CD86 on immature CD1cC DCs (Fig. S2B), whereas at the highest
tested concentration, it induced a slight but significant upregulation
of CD80 on immature pDCs (pD 0.0253; Fig. S2C). Thus, although
TNF-a plays a partial role in the crosstalk between pDCs and
CD1cC DCs, the cross activation of CD1cC by activated pDCs
seems predominantly mediated by IFN-a.
Combined application of CD1cC DCs and pDCs sustains
their capacity to activate lymphocytes
Following our observation that CD1cC DCs and pDCs could cross
activate each other, we investigated whether this may influence the
e1227902-2 J. J. P. VAN BEEK ET AL.
Figure 1. Human CD1cC DCs and pDCs cross activate each other. CD1cC DCs and pDCs were cultured overnight, either separately or together, in the presence of indi-
cated stimuli. Maturation was checked on the specific DC subsets within the co-culture. (A) Relative expression of CD86, CD80, PD-L1, and MHC class I and II on pDCs in
geometric MFI normalized to pDCs cultured alone with IL-3. (B) Relative expression of CD86, CD80, PD-L1 and MHC class I and II on CD1cC DCs in geometric MFI normal-
ized to CD1cC DCs cultured alone with GM-CSF. (C) IL-12p70, IFN-a, and TNF-a in supernatants of overnight cultures were analyzed by ELISA. Black bars, pDCs; white
bars, CD1cC DCs; gray bars, CD1cC DCs and pDCs. Results are the mean § SEM of at least five (A, B) or at least three (C) independent experiments. Significance was deter-
mined by repeated measures one-way ANOVA, followed by a post-hoc Dunnett’s test (p < 0.05; p < 0.01; p < 0.001). Only conditions that are significantly different
when compared with extra control groups (see Fig. S1) are denoted in the graphs.
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DCs’ ability to activate various immune effector cells. Since poly
(I:C) did not optimally mature CD1cC DCs in the presence of
CpG-C, stimulation by lipopolysaccharide (LPS) was included as
a condition in all further assays. LPS induced strong maturation
of mDCs, but not pDCs, while no significant IL-12 production
was induced (data not shown). First, a mixed lymphocyte reaction
(MLR) assay was performed to determine if DC co-cultures have
an effect on the proliferation and cytokine production of PBLs.
Expectedly, both CD1cC DCs and pDCs induced proliferation of
allogeneic PBLs. However, the combination of DC subsets did not
have an additive effect on PBL proliferation (Fig. 2, first panel).
Furthermore, both DC subsets induced IFN-g secretion in the
MLR, although higher IFN-g levels were reached with TLR-stimu-
lated CD1cC DCs than with pDCs (Fig. 2, second panel). Similar
to PBL proliferation, DC co-cultures did not yield superior IFN-g
production by PBLs. Collectively, these results clearly demonstrate
that human DC subsets, when cultured together, maintain their
capacity to induce PBL activation, yet without displaying any
synergy.
Co-cultures of CD1cC DCs and pDCs drive CD4C and CD8C
T cell polarization
DCs are important for the polarization of CD4C T cells into the
different T helper cell subsets, as well as the induction of CTLs
from naive CD8C T cells. Tumor-specific CD8C T cell responses
are critical for the eradication of tumor cells in cancer immuno-
therapy. In addition, tumor-specific CD4C T cells contribute to
CD8C T cell responses and their targeting enhances efficacy of
DC vaccination for treatment of melanoma patients.17,18 For this
purpose, these effector CD4C T cells should exhibit a Th1 phe-
notype, which is characterized by secretion of IFN-g.19 In sharp
contrast, differentiation of CD4C T cells into IL-10-secreting reg-
ulatory T cells inhibits adaptive immune responses and thereby
promotes tumor immune evasion.20 To determine if a combina-
tion of human blood DC subsets can efficiently polarize T cells
into effector cells that are favorable for cancer immunotherapy,
CD1cC DCs and/or pDCs were used to activate allogeneic naive
CD4C or CD8C T cells. T cell polarization was determined by
analyzing cytokine production profile of the induced T cells.
Both DC single cultures and DC co-cultures induced IFN-gC
CD4C T cells (Fig. 3A, first panel). Total IFN-g secretion in the
CD4C T cell cultures differed slightly between the different DC
stimuli, but no significant changes were detected for the combi-
nation of CD1cC DCs and pDC, compared to the use of either
subset alone (Fig. 3A, second panel). In addition, a favorable
ratio of IFN-g to IL-10 was induced in DC co-cultures and IL-
10 production in DC co-cultures was lower than in cultures with
CpG-C-activated pDCs (Fig. 3A, third panel). These results indi-
cate that the combination of CD1cC DCs and pDCs predomi-
nantly drives Th1 polarization, with low induction of regulatory
T cells. Finally, CD1cC DCs, pDCs or the combination of both
induced granzyme BC CD8C T cells, IFN-gC CD8C T cells and
TNF-aC CD8C T cells, with no significant advantage of DC co-
cultures over DC single cultures (Fig. 3B). Thus, combining
CD1cC DCs and pDCs does not further augment T cell polariza-
tion in comparison to the application of either DC subset alone.
Co-cultures of CD1cC DCs and pDCs promote plasma cell
differentiation of activated B cells
Although combined application of pDCs and CD1cC DCs did
not have an added value in T cell activation, we investigated
whether it has an effect on other immunological components
that are essential for tumor eradication. B cells have a crucial
role in antitumor immunity as antibody-secreting plasma
cells.21 Plasma cell differentiation from naive B cells can be pro-
moted by activated pDCs.22 We examined if this effect persists
in co-cultures of human CD1cC DCs and pDCs. Freshly iso-
lated CD1cC DCs and/or pDCs were incubated together with
autologous B cells in the presence of CpG-C and other stimuli
for 7 d. CpG-C acts as a stimulus for both pDCs and B cells,
and poly(I:C) or LPS was added to stimulate CD1cC DCs. In
sharp contrast to CD1cC DCs, activated pDCs enhanced
plasma cell differentiation of activated B cells (Fig. 4 A and B).
Combining DC subsets did not enhance the plasma cell-induc-
ing capacity of pDCs, which remained significantly higher in
comparison to CD1cC DC single cultures (p D 0.0095 for cul-
tures stimulated with CpG-C, p D 0.0004 for cultures stimu-
lated with CpG-C and poly(I:C), p D 0.0043 for cultures
stimulated with CpG-C and LPS). Thus, owing to the presence
Figure 2. Co-cultures of human CD1cC DCs and pDCs induce effector cell responses in a mixed lymphocyte reaction. After CD1cC DCs and/or pDCs were stimulated over-
night with indicated stimuli, they were cultured with allogeneic PBLs at a 10:1 PBL:DC ratio. Proliferation was determined at day 4 by [3H]-thymidine incorporation. IFN-g
in supernatants was analyzed at day 3 by ELISA. Black bars, pDCs with PBLs; white bars, CD1cC DCs with PBLs; gray bars, CD1cC DCs and pDCs with PBLs; striped bars,
PBLs only. Results are the mean § SEM of five (first panel) or three (second panel) independent experiments.
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of pDCs, DC co-cultures retain the ability to induce plasma cell
differentiation.
Combining CD1cC DCs and pDCs synergistically enhances
NK cell cytotoxicity
DCs do not only take part in the control of adaptive immunity, but
can also interact with innate immune cells such as NK cells. Both
IL-12 and IFN-a, cytokines secreted by human blood DCs, are
known activators of NK cells.23 Therefore, we investigated whether
a combination of human CD1cC DCs and pDCs is favorable for
the induction of NK cell responses. Both CD1cC DCs and pDCs
exerted the ability to enhance IFN-g secretion by IL-2-activated
NK cells, with poly(I:C)-stimulated CD1cCDCs inducing the high-
est IFN-g levels (Fig. 5A). Similar trends were seen in NK cell cul-
tures with both DC subsets: conditions in which poly(I:C) was used
as DC stimulus induced the highest IFN-g levels, but not to a
higher level than adding CD1cCDCs only.
In addition to IFN-g secretion, NK cell cytolytic activity, the
hallmark of NK functionality, was determined. Following their
activation by DCs, NK-killing of either the NK-sensitive K562
tumor cells or the NK-resistant Daudi tumor cells was deter-
mined by flow cytometry. Both CpG-C-stimulated pDCs and
poly(I:C)-stimulated CD1cC DCs enhanced the killing of K562
and Daudi tumor cells by autologous NK cells (Fig. 5 B and C).
When NK cells were activated by the combination of poly(I:C)-
stimulated CD1cC DCs and CpG-C-stimulated pDCs, a
significant further increase in Daudi cell killing was detected
(p D 0.0011 when compared to CpG-C-activated pDCs and
p D 0.0115 when compared to poly(I:C)-activated CD1cC DCs;
Fig. 5C). To exclude the possibility that this was merely an
effect of the combination of CpG-C and poly(I:C), both stimuli
were also tested on DC single cultures. When compared to DC
single cultures stimulated with both CpG-C and poly(I:C), the
increase in Daudi cell killing in the DC co-cultures remained
significant (p D 0.0010 when compared to pDCs and p D
0.0002 when compared to CD1cC DCs; Fig. S3).
In an attempt to investigate themechanism behind the observed
synergistic effect on NK-cytotoxicity, other CpG classes were used
to stimulate the DCs. Although CpG-A mainly induces the secre-
tion of high IFN-a levels by pDCs, CpG-B mainly elevates the
expression of co-stimulatory molecules.24 As expected, DC co-cul-
tures stimulated with CpG-A secreted more IFN-a than those
stimulated with CpG-C, whereas stimulation with CpG-B did not
lead to detectable levels of IFN-a (Fig. S4). When CpG-A was used
as stimulus in the DC co-cultures instead of CpG-C, higher levels
of NK-mediated Daudi cell killing were achieved (p D 0.0248;
Fig. 5D). In contrast, the use of CpG-B resulted in less killing,
although the difference was not statistically significant (p D
0.1603). Furthermore, addition of recombinant IFN-a to NK cells
alone also increased their cytotoxicity (p D 0.0237; Fig. 5E). These
results hint toward a role of IFN-a in the synergistic enhancement
of NK cell cytotoxicity in co-cultures of human CD1cC DCs and
pDCs, which is consistent with the observed increase in IFN-a pro-
duction in the DC co-cultures.
Figure 3. Co-cultures of human CD1cC DCs and pDCs activate and polarize naive CD4C and CD8C T cells. After CD1cC DCs and/or pDCs were stimulated overnight with
indicated stimuli, they were cultured with SEB and allogeneic naive CD4C (A) or CD8C (B) T cells at a 4:1 T cell:DC ratio. (A) Resting CD4C T cells were restimulated with
PMA/ionomycin in the presence of brefeldin A and intracellular IFN-g expression was measured by flow cytometry. In parallel, resting CD4C T cells were restimulated
with anti-CD3/CD28 beads and after 24 h, IFN-g and IL-10 in supernatants were analyzed by ELISA. Black bars, pDCs with CD4C T cells; white bars, CD1cC DCs with CD4C
T cells; gray bars, CD1cC DCs and pDCs with CD4C T cells. (B) Intracellular granzyme B expression by resting CD8C T cells was measured by flow cytometry. Resting CD8C
T cells were restimulated with PMA/ionomycin in the presence of brefeldin A and intracellular IFN-g and TNF-a expression was measured by flow cytometry. Black bars,
pDCs with CD8C T cells; white bars, CD1cC DCs with CD8C T cells; gray bars, CD1cC DCs and pDCs with CD8C T cells. Results are the mean § SEM of at least five (A, first
panel), four (A, second and third panels; B, second and third panels), or three (B, first panel) independent experiments.
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In summary, human blood CD1cC DCs and pDCs could
cross activate each other, while combined TLR-stimulation of
both subsets induced further changes, including increased
CD86 expression on pDCs and enhanced IFN-a production.
These crosstalk-mediated effects did not affect the DCs’ ability
to induce T cell polarization, but did augment NK cell-medi-
ated killing of an NK-resistant tumor cell line. Furthermore,
co-application of CD1cC DCs and pDCs allowed for comple-
mentation of subset-specific effector functions, such as induc-
tion of plasma cell differentiation from B cells and secretion of
high levels of IFN-g by PBLs and NK cells.
Discussion
Naturally occurring DCs might become a promising alternative
to monocyte-derived DCs for use in DC-based cancer immuno-
therapy.3 Our group previously conducted the first clinical tri-
als with ex vivo stimulated and TAA-pulsed primary human
DCs in metastatic melanoma patients and demonstrated the
safety, feasibility and proof of principle of this approach.15,16
Overall survival of patients that received a pDC vaccine was
greatly increased compared to matched controls and in 7 out of
15 patients an increase in TAA-specific CD8C T cells was
detected after vaccination.15 Of 14 patients that received a
CD1cC DC vaccine, 4 showed long-term progression-free sur-
vival, which correlated with multifunctional CD8C T-cell
responses in 3 of these patients.16 Others have shown that pri-
mary DCs might also be used for treatment of cancers other
than melanoma. Vaccination with TAA-pulsed CD1cC DCs for
advanced stage metastatic prostate cancer was considered feasi-
ble and safe.14 These positive results prompted us to investigate
whether a combination of primary DC subsets can further
enhance immunological responses.
A drawback of the use of primary DCs for immunotherapy
is that the number of DCs that can be isolated from peripheral
blood is relatively low. Combining CD1cC DCs and pDCs for
vaccination purposes would mean that a larger number of DCs
can be adoptively transferred, thereby potentially enhancing
immune responses. In addition, CD1cC DCs and pDCs are
functionally distinct and may interact differently with adaptive
and innate immune cells, suggesting that they might be able to
complement each other’s effector functions. Furthermore, sev-
eral in vitro and in vivo studies have demonstrated that direct
crosstalk between DC subsets can take place both in the human
Figure 4. Co-cultures of human CD1cC DCs and pDCs induce plasma cell differentiation. CD1cC DCs and/or pDCs were cultured with autologous B cells in the presence of
indicated stimuli. After 7 days, plasma cell differentiation was determined by flow cytometry. (A) Plasma cells were defined as CD38highCD20low expressing cells. (B) The
percentages of plasma cells in co-cultures with DCs. Black bars, pDCs with B cells; white bars, CD1cC DCs with B cells; gray bars, CD1cC DCs and pDCs with B cells; striped
bars, B cells only. Results are the representative or mean § SEM of three independent experiments. Significance was determined by repeated measures one-way ANOVA,
followed by a post-hoc Bonferroni’s test (p < 0.05; p < 0.01; p < 0.001).
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and murine setting and is mediated by soluble and contact-
dependent mechanisms.25,26 Evidence for synergy between
mouse DC subsets was found in a study by Lou et al., which
showed that immunization of mice with a mixture of mDCs
and activated pDCs improved antitumor responses, compared
to immunization with either subset alone.27
In this study, we compared co-cultures of CD1cC DCs and
pDCs to single cultures of either DC subset for their phenotype,
cytokine secretion and ability to induce effector cell responses.
The total amount of DCs was kept the same in DC single cul-
tures and DC co-cultures, to exclude cell number-dependent
effects. TLR agonists were added to mature one particular DC
subset: TLR-3 agonist poly(I:C) for CD1cC DCs and TLR-9
agonist CpG-C for pDCs. In line with previous findings,28,29 we
found that mature CD1cC DCs can activate immature pDCs
and vice versa. This cross activation effect could therefore also
play a role during DC vaccination therapy, where infused
mature DCs might propagate initial induced immune responses
by maturing host DCs.
One of the issues that needs to be considered when using
CD1cC DCs and pDCs into a combined vaccine is whether
these subsets should be maturated separately or together. Based
on the findings in this manuscript, should only one TLR ago-
nist specific to one of the subsets be used, then it is preferable
to stimulate the CD1cC DCs and pDCs together, so that the
mature subset can mediate cross activation of the other subset.
Also in the in vivo study by Lou et al., maturation of pDCs in
the presence of mDCs was crucial, as a mixture of mDCs and
separately activated pDCs did not result in enhanced antigen-
specific CD8C T cell responses.27 Since the mDCs in this model
were not stimulated by a TLR agonist, the observed synergistic
effect can be explained by the cross activation of the immature
mDCs by mature pDCs prior to vaccination. In an ideal DC
vaccine, however, both subsets should be fully activated, in
order to induce maximal immunological responses. Here, we
have shown that combined maturation of human blood DC
subsets using TLR agonists can also affect their phenotype and
functionality. pDCs cultured with CD1cC DCs in the presence
of poly(I:C) and CpG-C, upregulated CD86, compared to
pDCs receiving similar stimuli in the absence of CD1cC DCs.
However, although crosstalk between DC subsets leads to the
upregulation of co-stimulatory molecules, it also leads to upre-
gulation of PD-L1. While engagement of co-stimulatory mole-
cules enhances T cell activation, binding of PD-L1 to the PD-1
Figure 5. Co-cultures of human CD1cC DCs and pDCs enhance NK cell responses. CD1cC DCs and/or pDCs were cultured overnight with indicated stimuli. (A) Stimulated
DCs were subsequently cultured with autologous NK cells at a 1:1 ratio and with IL-2. IFN-g in 24 h supernatants was analyzed by ELISA. (B–E) Stimulated DCs were cul-
tured with autologous NK cells at a 5:1 NK cell:DC ratio for 24 h. Labeled K562 or Daudi tumor cells were added for the last 4 h of the culture at 5:1 NK cell:target cell ratio.
Specific target cell killing was determined by flow cytometry. Black bars, pDCs with NK cells; white bars, CD1cC DCs with NK cells; gray bars, CD1cC DCs and pDCs with NK
cells; striped bars, NK cells only. Results are the mean§ SEM of at least four (A, B), five (C), or three (D, E) independent experiments. Significance in (C) was determined by
repeated measures one-way ANOVA, followed by a post-hoc Dunnett’s test (p< 0.05; p< 0.01; p< 0.001), and only conditions showing significant differences in all
comparisons, are denoted in the graph. Significant differences among experimental conditions in (D) were determined by one-way ANOVA followed by a post-hoc Bonfer-
roni’s test (p < 0.05; p < 0.01; p < 0.001). Significant differences among experimental conditions in (E) were determined by two-tailed Student’s t-test on paired
samples (p< 0.05; p < 0.01; p < 0.001).
ONCOIMMUNOLOGY e1227902-7
receptor on T cells provides an inhibitory signal that suppresses
T cell activation.30 Besides changing their expression of surface
molecules, co-cultures of CD1cC DCs and pDCs stimulated
with poly(I:C) and CpG-C produced more IFN-a than single
cultures of stimulated pDCs. The difference was significant
even though the absolute number of pDCs, the main producers
of IFN-a, in the DC co-cultures was half of the amount present
in the DC single cultures. IFN-a can, among other effects,
induce Th1 skewing of naive CD4C T cells,12 which in turn
contributes to the antitumor immune response.
To determine the overall effect of CD1cC DC-pDC crosstalk
on T cell responses, we cultured stimulated DCs with naive
CD4C T cells or naive CD8C T cells. No significant changes in
cytokine production by the T cells were observed for the com-
bination of DC subsets compared to the use of single DC sub-
sets. Hence, combining CD1cC DCs with pDCs does not seem
to negatively alter their ability to induce CD4C and CD8C T
cell responses. However, the observed upregulation of PD-L1
in the DC co-cultures, suggests that certain DC vaccines might
benefit from the combination with blocking antibodies directed
against PD-L1 and/or PD-1. Thus, a combination of DC sub-
sets may synergistically enhance T cell responses, when used in
conjunction with these checkpoint inhibitors.
Besides efficiently priming naive T cells, DCs possess the abil-
ity to activate other immune effector cells, including B cells and
NK cells. NK cells are critical for the antitumor immune
response, but the role of B cells in tumor immunity is controver-
sial.31-37 Nevertheless, it has recently been reported that antibod-
ies directed against tumor cells can promote antitumor
responses by facilitating enhanced uptake of tumor antigens by
DCs. 38 In addition, tumor cell-specific antibodies can mediate
complement dependent and cell dependent cytotoxicity.21 Anti-
bodies are mainly produced by plasma cells, which develop from
activated B cells. We have shown that pDCs are superior to
CD1cC DCs at enhancing plasma cell differentiation from acti-
vated B cells. In contrast, CD1cC DCs outperformed pDCs at
enhancing IFN-g production in both an MLR assay and in cul-
ture with activated autologous NK cells. The advantage of one
particular DC subset was retained when the subsets were com-
bined. Thus, human blood mDCs and pDCs can complement
each other’s effector functions, even when cultured together.
CTLs can detect and lyse transformed cells in an antigen-
dependent manner, by recognizing neo-antigens or overex-
pressed self-antigens. DC vaccine-based immunotherapy has
therefore historically focused at inducing strong CD8C T cell
responses. However, the importance of DC interactions with
innate cells for clinical outcome is now becoming more appre-
ciated.39 NK cells form the body’s main line of defense against
tumor cells that downregulate MHC class I to evade detection
by CTLs. Besides reacting to a loss of inhibitory ligands, NK
cells possess activating receptors that recognize stress-induced
ligands on tumor cells. NK cells do not necessarily require prior
activation to lyse target cells and in our experiments they could
efficiently kill K562 tumor cells. Still, addition of poly(I:C)-acti-
vated CD1cC DCs, CpG-C-activated pDCs or both to the cul-
ture enhanced NK cell cytotoxicity. However, other tumor cells
may be more resistant to NK cell-mediated killing. In order to
lyse such target cells, NK cell do require prior stimulation. In
line with previous findings,40 we found that NK cells alone only
induce minor killing of Daudi tumor cells, but culture of NK
cells with poly(I:C)-activated CD1cC DCs or CpG-C-activated
pDCs enhanced their killing potential. Moreover, the combina-
tion of both DC subsets further increased the killing. This syn-
ergistic effect is most likely mediated by the increased amount
of IFN-a produced by the DC co-cultures, as replacement of
CpG-C by CpG-A to mature DCs further enhanced NK-medi-
ated Daudi cell killing, while use of CpG-B instead lowered the
killing. No synergistic increase in NK-mediated killing could be
detected in our assays with K562 tumor cells, most likely
because optimal killing is already achieved when one of the DC
subsets is added.
Our results indicate that combining CD1cC DCs and pDCs
for therapeutic purposes can have beneficial effects. Further-
more, stimulation of CD1cC DCs and pDCs together allows for
direct crosstalk between the subsets, which can alter their pheno-
type and functionality. However, using multiple stimuli to facili-
tate maturation of DC subsets in co-culture may have
additional, non-crosstalk-related effects. CD1cC DCs did not
optimally mature in the presence of both poly(I:C) and CpG-C:
the increase in co-stimulatory molecules was lower than when
CpG-C was absent and no detectable levels of IL-12p70 were
produced. This can have consequences for their effector func-
tion, as DC co-cultures that received poly(I:C) and CpG-C
induced lower IFN-g levels in both an MLR assay and in culture
with autologous NK cells, than when poly(I:C) and IL-3 were
used as stimuli. The inhibitory effect of CpG ODN on poly(I:C)-
induced DC maturation has been described before for mono-
cyte-derived DCs.41 We therefore took along LPS as a stimulus
for CD1cC when they were subsequently cultured with effector
cells. Although CD1cC DCs stimulated with this TLR-4 agonist
express high levels of co-stimulatory molecules, they do not
secrete detectible levels of IL-12p70.8 This is likely the reason
why LPS-stimulated CD1cC DCs were unable to enhance IFN-g
production or tumor cell killing by autologous NK cells. Ideally,
the DC subsets should be stimulated in such a way that pDCs
secrete high levels of IFN-a and CD1cC DCs secrete high levels
of bioactive IL-12. While CpG ODN inhibits poly(I:C)-induced
DC maturation, a combination of other TLR agonists may actu-
ally enhance DC activation.42 Alternatively, both DC subsets can
be stimulated with a single TLR agonist. Our group recently
established a clinical-grade stimulus that can activate both
CD1cC DCs and pDCs in the form of stabilized RNA com-
plexes.43 The use of such a stimulus would be optimal to exploit
the advantages of both DC subsets in a clinical setting.
Taken together, a combination of CD1cC DCs and pDCs
allows for complementation or even enhancement of each
other’s effector functions. Hence, combining different human
blood DC subsets holds promise for improvement of current
DC-based anticancer vaccines.
Materials and methods
Cell isolation
Primary cells were isolated from buffy coats of healthy individ-
uals (Sanquin) after informed consent and according to institu-
tional guidelines. Peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll density centrifugation (Lymphoprep;
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Axis-Shield PoC). B cells were isolated from PBMCs with a pan
B cell isolation kit (Miltenyi Biotec, 130-101-638). CD1cC DCs
were isolated from PBMCs with a CD1cC DC isolation kit (Mil-
tenyi Biotec, 130-090-506), after depleting CD14C cells with
anti-CD14-conjugated microbeads (Miltenyi Biotec, 130-050-
201). PBLs were prepared by depleting PBMCs of monocytes
with anti-CD14-conjugated microbeads or via adherence to
plastic culture flasks. pDCs were isolated from PBLs with a
pDC isolation kit (Miltenyi Biotec, 130-090-532). Naive CD4C
T cells were isolated by enriching PBLs for CD4C T cells with a
CD4C T cell isolation kit (Miltenyi Biotec, 130-096-533) and
subsequently depleting CD45ROC memory T cells with anti-
CD45RO-PE (Dako, R084301) and anti-PE-conjugated
microbeads (Miltenyi Biotec, 130-048-801). Naive CD8C T cells
and NK cells were isolated from PBLs with a naive CD8C T
cells isolation kit (Miltenyi Biotec, 130-093-244) and an NK
cell isolation kit (Miltenyi Biotec, 130-092-657), respectively.
Cell purity was up to 98% as assessed by double staining for
CD1c/CD11c, BDCA2/CD123, CD4/CD45RA, CD8/CD45RA,
CD56/CD3, and CD19/CD3 for CD1cC DC, pDC, naive CD4C
T cell, naive CD8C T cell, NK cell, and B cell fractions,
respectively.
All isolated human peripheral cells were cultured in
X-VIVO 15 medium (Lonza, BE04-418Q) supplemented with
2% human serum (Sanquin).
DC activation
The following TLR ligands were used for DC stimulation: 5 mg/
mL CpG-C (ODN M362; Enzo Life Sciences, ALX-746-004),
5 mg/mL CpG-A (ODN 2216; Enzo Life Sciences, ALX-746-
005) or 5 mg/mL CpG-B (ODN 2006; Enzo Life Sciences,
ALX-746-006) for pDCs and 20 mg/mL poly(I:C) (Enzo Life
Sciences, ALX-746-021) or 1 mg/mL LPS (Sigma-Aldrich,
L4391-10£1MG) for CD1cC DCs. In the absence of their
respective TLR ligands, 10 ng/mL IL-3 (CellGenix, 1002-050)
was added to increase pDC viability and 450 U/mL GM-CSF
(CellGenix, 1012–050) was added for CD1cC DCs. Where indi-
cated, DCs were also incubated in the presence of increasing
concentrations of IFN-a-2a (Roferon-A; Roche) or TNF-a
(CellGenix, 1006).
Cell lines
The human NK-sensitive K562 tumor cell line was obtained
from the American Type Culture Collection (ATCC, catalog
number: K-562 ATCC CCL-243). The human NK-resistant
Daudi tumor cell line was obtained from ATCC (catalog num-
ber: Daudi ATCC CCL-213) and kindly provided to us by the
laboratory of Prof Kris Thielemans (Free University of Brussels,
Brussels, Belgium). Both cell lines were cultured in Iscove’s
modified Dulbecco’s medium (Invitrogen, 12440053) supple-
mented with 10% fetal bovine serum (Greiner Bio-One) and
1% antibiotic antimycotic (Gibco, 15240062).
Phenotype and cytokine secretion of stimulated DCs
CD1cC DCs and pDCs were incubated overnight at 37C with
different stimuli in a 96-well round-bottom plate, either
separate or together at a 1:1 ratio, with each well containing
equal cell numbers (50 £ 103 cells in 100 mL). After overnight
culture, supernatants were taken and cells were stained with
the following primary monoclonal antibodies: anti-human leu-
kocyte antigen (HLA)-ABC-APC (BD Biosciences, 555555),
anti-HLA-DR/DP/DQ-FITC (BD Biosciences, 555558), anti-
CD80-PE (BD Biosciences, 557227), anti-CD83-FITC (BD Bio-
sciences, 556910), anti-CD83-APC (BD Biosciences, 551073),
anti-CD86-PE (BD Biosciences, 555658), anti-PDL-1-PE
(BD Biosciences, 557924), anti-CD40-PE (Beckman Coulter,
PN IM1936U), anti-CCR7-PE (Miltenyi Biotec, 130-093-621).
Anti-CD11c-PE (BD Biosciences, 333149) or anti-CD123-APC
(Miltenyi Biotec, 130-090-901) primary monoclonal antibodies
were used to distinguish between DC subsets in co-cultures.
Samples were measured on a FACSCalibur or FACSVerse (BD
Biosciences) and analyzed by FlowJo software (TreeStar, Inc.).
The results are depicted as geometric mean fluorescence inten-
sity (MFI) normalized to the negative control. Supernatants
were analyzed for IL-12p70 (Thermo Fisher Scientific, M122),
TNF-a (eBioscience, 88-7346-88) and IFN-a (Bender Medsys-
tems, BMS216MST) by sandwich ELISA.
Mixed lymphocyte reaction
CD1cC DCs and pDCs were incubated overnight at 37C with
different stimuli in a 96-well round-bottom plate, either sepa-
rate or together at a 1:1 ratio, with each well containing equal
cell numbers. After overnight culture, DCs were washed with
culture medium to remove residual stimuli before subsequent
culture with effector cells.
The ability of DCs to induce T cell proliferation and cyto-
kine production was tested in an MLR, using 100 £ 103 alloge-
neic PBLs that were added to the DCs at a 10:1 ratio (PBL:DC)
in 200 mL and incubated for 4 d at 37C. On day 3, superna-
tants were taken and analyzed for IFN-g (Thermo Fisher Scien-
tific, M700A) by sandwich ELISA. Cellular proliferation was
analyzed by measuring overnight [3H]-thymidine (1 mCi/well;
MP Biomedicals, 2407005) incorporation on day 4 with a b
counter.
CD4C T cell polarization
CD1cC DCs and pDCs were stimulated as above and co-cul-
tured with allogeneic naive CD4C T cells at a 4:1 ratio (T cell:
DC) in the presence of 10 pg/mL Staphylococcal enterotoxin B
(SEB; Sigma-Aldrich, S4881). Proliferating cells at day 5 were
transferred to 48-well plates and refreshed every other day with
medium supplemented with 20 U/mL IL-2 (Proleukin,
Chiron) until cells were resting around day 11. 100 £ 103 rest-
ing T cells were restimulated by anti-CD3/CD28 beads (1 bead
per T cell; Gibco, 11131D) in 100 mL and after 24 h the levels
of IL-10 (eBioscience, 88-7106-77) and IFN-g were determined
in supernatants by sandwich ELISA. In parallel, resting CD4C
T cells were restimulated by phorbol 12-myristate 13-acetate
(PMA; Merck Millipore, 524400)/ionomycin (Sigma-Aldrich,
I0634) in the presence of brefeldin A (Sigma-Aldrich, B6542)
for 6 h, after which cells were fixed with 4% paraformaldehyde
(Merck Millipore, 104005), permeabilized with saponin (Sigma-
Aldrich, 84510) and stained with anti-IFN-g-PerCp-Cy5.5
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(BD Biosciences, 560704). Samples were measured on a CyAn
ADP (Beckman Coulter).
Naive CD8C T cell activation
CD1cC DCs and pDCs were stimulated as above and co-cul-
tured with allogeneic naive CD8C T cells at a 4:1 ratio (T cell:
DC) in the presence of 1 pg/mL SEB. Expression of granzyme
B by CD8C T cells was measured on day 5 by intracellular
staining using anti-GrB-PE antibody (Sanquin, M2289). To
detect intracellular cytokine production, CD8C T cells were
restimulated on day 6 with PMA/ionomycin in the presence of
brefeldin A for 6 h and after fixation and permeabilization,
stained with anti-IFN-g-PerCp-Cy5 and anti-TNF-a-PE (Biol-
egend, 502909). Samples were measured on a CyAn ADP.
Plasma cell differentiation
In contrast to the other effector cell assays, B cells were co-cul-
tured directly with freshly isolated DCs. Autologous B cells
were incubated with or without DCs at a 10:1 ratio (B cell:DC)
in the presence of different stimuli, for 7 d at 37C. DCs were
CD1cC DCs, pDCs or a combination of both at a 1:1 ratio, with
each well containing equal total DC numbers. After 7 d, B cells
were stained with CD20-APC (eBioscience, 17-0209-42) and
CD38-PE (ImmunoTools, 21270384) or CD38-PerCP-Cy5.5
(BD Biosciences, 551400) and a viability dye (Fixable Viability
Dye eFluor 780 or 506; eBioscience, 65-0865-18 or 65-0866-18)
and measured on a FACSVerse. Plasma cells were defined as
CD38highCD20low expressing cells.
NK cell activation and cytotoxicity
CD1cC DCs and pDCs were stimulated as mentioned for the
MLR assay, co-cultured with 100 £103 autologous NK cells at a
1:1 ratio in 200 mL and incubated for 24 h at 37C in the pres-
ence of 100 U/mL IL-2. NK cells cultured without DCs, but
with IL-2 or IL-2 and 1 ng/mL IL-12p70 (BD Biosciences,
554613), were used as controls. Supernatants were taken after
24 h and analyzed for IFN-g by sandwich ELISA.
For cytotoxicity assays, CD1cC DCs and pDCs were stimu-
lated as above, co-cultured with autologous NK cells at a 5:1
ratio (NK:DC) and incubated for 24 h at 37C. NK cells cul-
tured without DCs and with or without 10 ng/mL IFN-a-2a
(Roferon-A; Roche) were used as reference. Target cells
(K562 or Daudi) were labeled with PKH67 green fluorescent
cell linker (Sigma-Aldrich, MIDI67-1KT) according to manu-
facturer’s instruction and added to the NK cell cultures for the
last 4 h of the culture at an NK cell:target cell ratio of 5:1. Tar-
get cells cultured without NK cells were used as negative con-
trol. Cell death was determined after staining with propidium
iodide (PI; Biolegend, 1056–1) and annexin-V-APC (BD Bio-
sciences) in annexin-V binding buffer (BD Biosciences,
550475). Samples were measured on a FACSVerse or FACSAria
II (BD Biosciences). Specific killing of target cells was calculated
using the formula: %killing D 100 ¡ [(%Annexin¡V¡PI¡ tar-
get cells with NK cells/%Annexin¡V¡PI¡ target cells without
NK cells) £ 100].44
To assess IFN-a secretion by DC co-cultures during the
cytotoxicity assay, CD1cC DCs and pDCs were stimulated as
above (20 £103 cells in 100 mL). After 12 h of overnight cul-
ture, supernatants were taken, and DCs were washed with cul-
ture medium to remove residual stimuli before subsequent
culture of 24 h, after which supernatants were again taken. As a
control, supernatants were also taken of DCs cultured for 36 h
without washing.
Statistical analysis
GraphPad Prism software (v6.01) was used for statistical analy-
sis. For multiple comparisons, repeated measures one-way
ANOVA was performed, followed by post-hoc Dunnett’s test
when comparisons were made with one group, or Bonferroni’s
test when comparisons were made with all groups, to detect sta-
tistical significant differences between groups. For single com-
parisons, paired Student’s t-tests were performed to detect
statistical significant differences between groups. p-Values
< 0.05 were considered statistically significant (p < 0.05;
p < 0.01; p < 0.001).
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